Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression-Reference-Cited by-同舟云学术

Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression

Published:2021-07-01 Issue:14 Volume:64 Page:10333-10349
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Meng¹²,Aguilar Angelo¹²,Xu Shilin¹²^ORCID,Huang Liyue¹²,Chinnaswamy Krishnapriya³,Sleger Taryn⁴,Wang Bo⁴,Gross Stefan⁴,Nicolay Brandon N.⁴,Ronseaux Sebastien⁴,Harvey Kaitlin¹²,Wang Yu¹²,McEachern Donna¹²,Kirchhoff Paul D.¹²,Liu Zhaomin¹²,Stuckey Jeanne³,Tron Adriana E.⁴,Liu Tao⁴,Wang Shaomeng¹²⁵⁶^ORCID

Affiliation:

1. Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States

2. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States

3. Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, United States

4. Agios Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, United States

5. Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States

6. Department of Medicinal Chemistry, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

National Cancer Institute

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00789

Reference38 articles.

1. MLL rearrangements in haematological malignancies: lessons from clinical and biological studies

2. Mechanisms of leukemogenesis by MLL fusion proteins

3. The molecular biology of mixed lineage leukemia

4. The MLL recombinome of acute leukemias in 2017

5. HOXA9 is required for survival in human MLL-rearranged acute leukemias

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Menin signaling and therapeutic targeting in breast cancer;Current Problems in Cancer;2024-08

2. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia;International Journal of Molecular Sciences;2024-05-30

3. Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors;European Journal of Medicinal Chemistry;2024-03

4. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation;Oncology and Therapy;2024-02-01

5. Small molecules targeting protein–protein interactions for cancer therapy;Acta Pharmaceutica Sinica B;2023-10